Atossa Genetics Inc. (NASDAQ:ATOS) Given Average Rating of “Hold” by Analysts

by · The Markets Daily

Shares of Atossa Genetics Inc. (NASDAQ:ATOS – Get Free Report) have been assigned an average rating of “Hold” from the five analysts that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $6.25.

Several analysts have commented on ATOS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, October 8th. Ascendiant Capital Markets raised their target price on Atossa Genetics from $7.50 to $7.75 and gave the company a “buy” rating in a research note on Monday, September 22nd. Finally, Zacks Research cut Atossa Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th.

Check Out Our Latest Report on Atossa Genetics

Atossa Genetics Stock Up 5.5%

NASDAQ:ATOS opened at $0.74 on Thursday. The firm’s fifty day simple moving average is $0.88 and its 200 day simple moving average is $0.85. The stock has a market cap of $95.39 million, a P/E ratio of -3.08 and a beta of 0.95. Atossa Genetics has a twelve month low of $0.55 and a twelve month high of $1.30.

Atossa Genetics (NASDAQ:ATOS – Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). On average, analysts expect that Atossa Genetics will post -0.22 EPS for the current fiscal year.

Institutional Trading of Atossa Genetics

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Atossa Genetics by 4.2% during the third quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after buying an additional 245,717 shares during the last quarter. Ameriprise Financial Inc. bought a new position in shares of Atossa Genetics during the second quarter valued at $2,468,000. Jane Street Group LLC purchased a new position in shares of Atossa Genetics in the 2nd quarter worth about $381,000. Charles Schwab Investment Management Inc. boosted its stake in Atossa Genetics by 40.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company’s stock worth $284,000 after purchasing an additional 120,934 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its position in Atossa Genetics by 357.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after purchasing an additional 325,340 shares during the last quarter. 12.74% of the stock is owned by institutional investors.

About Atossa Genetics

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

See Also